These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1281960)

  • 21. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
    Peuskens J
    Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.
    Peralta V; Cuesta MJ
    Psychiatry Res; 1994 Jul; 53(1):31-40. PubMed ID: 7991730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
    Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):295-305. PubMed ID: 1375801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validating specific psychopathology scales in older outpatients with schizophrenia.
    McAdams LA; Harris MJ; Bailey A; Fell R; Jeste DV
    J Nerv Ment Dis; 1996 Apr; 184(4):246-51. PubMed ID: 8604035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pharmacotherapeutic modalities for negative symptoms in psychosis.
    Lindenmayer JP
    Acta Psychiatr Scand Suppl; 1995; 388():15-9. PubMed ID: 7541598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability and validity of the positive and negative syndrome scale for schizophrenics.
    Kay SR; Opler LA; Lindenmayer JP
    Psychiatry Res; 1988 Jan; 23(1):99-110. PubMed ID: 3363019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone: clinical development: north American results.
    Marder SR
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():92A-93A. PubMed ID: 1379883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment.
    Czobor P; Volavka J
    Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS.
    Norman RM; Malla AK; Cortese L; Diaz F
    Schizophr Res; 1996 Mar; 19(1):73-85. PubMed ID: 9147498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 34. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
    Volpi S; Potkin SG; Malhotra AK; Licamele L; Lavedan C
    J Clin Psychiatry; 2009 Jun; 70(6):801-9. PubMed ID: 19573479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity.
    Bell M; Milstein R; Beam-Goulet J; Lysaker P; Cicchetti D
    J Nerv Ment Dis; 1992 Nov; 180(11):723-8. PubMed ID: 1431824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The negative component in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 1995; 388():11-4. PubMed ID: 7541597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.